New Product Slideshows

A collection of informative slideshows for the latest in drug product releases

  • LIPTRUZET

    Indication(s): To reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in primary or mixed hyperlipidemia.

  • TECFIDERA

    Indication(s): Treatment of patients with relapsing forms of multiple sclerosis.

  • POMALYST

    Indication(s): Multiple myeloma, in patients who have received at least two prior therapies (including lenalidomide and bortezomib).

  • KYNAMRO

    Indication(s): Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C).

  • KADCYLA

    Indication(s): Treatment in patients with HER2-positive (+), metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination.

  • INVOKANA

    Indication(s): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).

  • AUVI-Q

    Indication(s): Emergency treatment of allergic reactions (Type 1) including anaphylaxis.

New Products

GIAZO

GIAZO

  • 6/16/2013
  • Salix Pharmaceuticals, Inc.
  • Balsalazide disodium (prodrug of mesalamine) 1.1g; tabs; contains sodium 126mg/tab.
  • Treatment of mildly-to-moderately active ulcerative colitis in male patients.

    Limitations of use: effectiveness in treatment of female patients was not demonstrated. Safety and effectiveness of therapy beyond 8 weeks have not been established.

LIPTRUZET

LIPTRUZET

  • 6/9/2013
  • Merck Co., Inc.
  • Ezetimibe/atorvastatin; 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg; tabs.
  • To reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in primary (heterozygous familial and non-familial) or mixed hyperlipidemia. To reduce elevated total-C and LDL-C in homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable. Limitations of use: No incremental benefit on cardiovascular morbidity/mortality over and above that demonstrated for atorvastatin has been established. Not studied in Fredrickson type I, III, IV, and V dyslipidemias.
TECFIDERA

TECFIDERA

  • 6/2/2013
  • Biogen Idec, Inc.
  • Dimethyl fumarate 120mg, 240mg; delayed-release caps.
  • Treatment of patients with relapsing forms of multiple sclerosis.
POMALYST

POMALYST

  • 5/26/2013
  • Celgene Corp
  • Pomalidomide 1mg, 2mg, 3mg, 4mg; capsules.
  • Multiple myeloma, in patients who have received at least two prior therapies (including lenalidomide and bortezomib), and have shown disease progression on or within 60 days of completion of the last therapy. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
KYNAMRO

KYNAMRO

  • 5/19/2013
  • Genzyme Corporation
  • Mipomersen sodium 200mg/mL; soln for SC inj; preservative-free.
  • Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
KADCYLA

KADCYLA

  • 5/12/2013
  • Genentech, Inc.
  • Ado-trastuzumab emtansine 100mg, 160mg; per vial; powder; for IV infusion after reconstitution.
  • Treatment in patients with HER2-positive (+), metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy.
INVOKANA

INVOKANA

  • 5/5/2013
  • Janssen Pharmaceuticals, Inc.
  • Canagliflozin 100mg, 300mg; tablets.
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). Limitation of use: not for treatment of type 1 diabetes or diabetic ketoacidosis.
AUVIQ

AUVIQ

  • 4/28/2013
  • Sanofi Aventis
  • Epinephrine 0.3mg, 0.15mg; pre-filled auto-injector (includes audible and visible cues for use).
  • Emergency treatment of allergic reactions (Type 1) including anaphylaxis.
VARIZIG

VARIZIG

  • 4/21/2013
  • Cangene Corporation
  • Varicella zoster immune globulin (human) 125 IU; per vial; lyophilized pwd for IM inj after reconstitution; contains <250mg of total protein (mostly human IgG), <40mcg/mL of IgA; preservative- and mercury-free.
  • Postexposure prophylaxis of varicella in high risk individuals (include immunocompromised children and adults, newborns of mothers with varicella shortly before or after delivery, premature infants, neonates and infants <1 year old, adults without evidence of immunity, pregnant women). To reduce severity of varicella.
MINIVELLE

MINIVELLE

  • 4/14/2013
  • Noven Therapeutics
  • Estradiol 0.0375mg/day, 0.05mg/day, 0.075mg/day, 0.1mg/day; transdermal patch.
  • Moderate-to-severe vasomotor symptoms due to menopause.
SIGNIFOR

SIGNIFOR

  • 4/7/2013
  • Novartis Pharmaceuticals Corp
  • Pasireotide diaspartate 0.3mg/mL, 0.6mg/mL, 0.9mg/mL; soln for SC inj.
  • Treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
MARQIBO

MARQIBO

  • 3/31/2013
  • Talon Therapeutics, Inc.
  • Vincristine sulfate liposome injection; after preparation, each vial contains 0.16mg/mL; for IV infusion.
  • Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or has progressed following ≥2 anti-leukemia therapies.
ICLUSIG

ICLUSIG

  • 3/24/2013
  • ARIAD Pharmaceuticals, Inc.
  • Ponatinib 15mg, 45mg; tabs.
  • Chronic, accelerated, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
SKYLA

SKYLA

RAYOS

RAYOS

  • 3/10/2013
  • Horizon Pharma
  • Prednisone 1mg, 2mg, 5mg; delayed-release tablets.
  • Corticosteroid-responsive disorders.
SYNRIBO

SYNRIBO

  • 3/3/2013
  • Teva Pharmaceuticals
  • Omacetaxine mepesuccinate 3.5mg/vial; lyophilized powder for SC injection after reconstitution; contains mannitol; ­preservative-free.
  • Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
ELIQUIS

ELIQUIS

  • 2/24/2013
  • BristolMyers Squibb and Pfizer
  • Apixaban 2.5mg, 5mg; tablets.
  • To reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).
UCERIS

UCERIS

  • 2/17/2013
  • Santarus, Inc.
  • Budesonide 9mg; extended-release tabs.
  • Induction of remission in patients with active, mild-to-moderate ulcerative colitis.
OXTELLAR XR

OXTELLAR XR

  • 2/10/2013
  • Supernus Pharmaceuticals
  • Oxcarbazepine 150mg, 300mg, 600mg; extended-release tablets.
  • Adjunctive therapy in the treatment of partial seizures in adults and in children 6–17 years of age.
VASCEPA

VASCEPA

  • 2/3/2013
  • Amarin Pharma
  • Icosapent ethyl 1g; soft gelatin capsules.
  • Adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500mg/dL) hypertriglyceridemia. Limitations of use: The effect of Vascepa on the risk for pancre­atitis in patients with severe hypertriglyceridemia has not been determined. The effect of Vascepa on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.
More »